Phase I Dose-Escalation Study of Tirapazamine Chemoembolization for Unresectable Early- and Intermediate-Stage Hepatocellular Carcinoma

Liu, Chang-HsienChang-HsienLiuPeng, Cheng-MingCheng-MingPengHwang, Jen-IJen-IHwangPO-CHIN LIANGPEI-JER CHENAbi-Jaoudeh, NadineNadineAbi-JaoudehGiiang, Lung-HuiLung-HuiGiiangTyan, Yu-ShenYu-ShenTyan2022-11-072022-11-0720221051-0443https://scholars.lib.ntu.edu.tw/handle/123456789/624464To investigate the safety of replacing doxorubicin with tirapazamine in conventional transarterial chemoembolization (TACE) in an Asian population with hepatocellular carcinoma (HCC), and to determine the optimal tirapazamine dose for phase II studies.enTRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; DRUG-ELUTING BEADS; CANCER STEM-CELLS; TRANSARTERIAL CHEMOEMBOLIZATION; RANDOMIZED-TRIAL; LIVER-TUMORS; III TRIAL; EMBOLIZATION; HYPOXIA; CISPLATIN[SDGs]SDG3Phase I Dose-Escalation Study of Tirapazamine Chemoembolization for Unresectable Early- and Intermediate-Stage Hepatocellular Carcinomajournal article10.1016/j.jvir.2022.04.031355044362-s2.0-85130896475WOS:000863452400002https://api.elsevier.com/content/abstract/scopus_id/85130896475